Related Experiment Video

Updated: Feb 17, 2026

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes
07:22

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Published on: March 7, 2025

1.0K

Cardiovascular mortality and oral antidiabetic drugs: protocol for a systematic review and network meta-analysis

Rashmi Goyat1, James Douglas Thornton2, Xi Tan1

  • 1Department of Pharmaceutical Systems and Policy, School of Pharmacy, West Virginia University, Morgantown, West Virginia, USA.

BMJ Open
|December 3, 2017
PubMed

Insights

This systematic review compares oral antidiabetic drugs (ADDs) for cardiovascular safety. It aims to determine which ADDs pose the greatest risk for cardiovascular mortality in diabetic patients.

Area of Science:

  • Pharmacology
  • Cardiology
  • Endocrinology

Background:

  • Cardiovascular diseases (CVD) are a major cause of death in diabetic individuals.
  • Some antidiabetic drugs (ADDs) that lower HbA1c may increase CVD risk.
  • Evaluating ADDs' cardiovascular safety is crucial due to high CVD prevalence in diabetes.

Purpose of the Study:

  • To systematically review and network meta-analyze the cardiovascular safety of various oral antidiabetic drug classes.
  • To compare the risks of cardiovascular events associated with different ADDs.

Main Methods:

  • Systematic review and network meta-analysis of randomized clinical trials and observational studies up to January 2017.
  • Searched four electronic databases; dual data selection and abstraction.
  • Primary outcome: cardiovascular mortality; secondary outcomes: all-cause mortality, myocardial infarction, stroke, etc.

Main Results:

  • The study will present a hierarchy of ADDs based on their potential to increase cardiovascular mortality.
  • Results will be disseminated via conference presentation and peer-reviewed publication.

Conclusions:

  • The findings will inform clinical decisions regarding ADD selection for diabetic patients, balancing glycemic control with cardiovascular risk.
  • This research provides critical evidence for optimizing diabetes management to reduce cardiovascular morbidity and mortality.
Abstract

Keywords:
network meta-analysissystematic review

More Related Videos

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

26.6K

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
698
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
612
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
4.3K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
705
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
1.2K
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
278